Amyotrophic Lateral Sclerosis: Clinical Trials

978 trials for Amyotrophic Lateral Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

436 completed, 170 recruiting, 126 unknown, 70 terminated. 274 Phase 2, 235 Not applicable, 172 Phase 1, 90 Phase 3, 20 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2274Completed 149, Unknown 28, Recruiting 26, Terminated 26, Active not recruiting 14, Not yet recruiting 14, Withdrawn 11, Enrolling by invitation 4, Suspended 2
Not applicable235Completed 89, Recruiting 61, Unknown 35, Not yet recruiting 12, Active not recruiting 11, Withdrawn 11, Terminated 9, Enrolling by invitation 5, Suspended 2
Phase 1172Completed 76, Recruiting 24, Unknown 20, Not yet recruiting 14, Terminated 14, Active not recruiting 11, Withdrawn 7, Enrolling by invitation 4, Suspended 2
Phase 390Completed 49, Terminated 16, Unknown 8, Recruiting 7, Active not recruiting 5, Not yet recruiting 5
Early Phase 120Completed 9, Not yet recruiting 5, Recruiting 4, Active not recruiting 1, Withdrawn 1
Phase 48Completed 4, Unknown 2, Active not recruiting 1, Recruiting 1

Follow Amyotrophic Lateral Sclerosis: new trials by email Literature Review of Amyotrophic Lateral Sclerosis trials Research Report on Amyotrophic Lateral Sclerosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162028-09-012026-09-11
Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)
B cell infusion - ALS - Amyotrophic Lateral Sclerosis
Phase 1Not yet recruitingMark Poznansky102027-09-012026-09-24
Safety Study of XT-150 in Participants With ALS
XT-150 - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingXalud Therapeutics, Inc.82027-03-012026-07-29
A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NI112, Placebo - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingSachi Bioworks Inc.402027-01-222026-10-30
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
INTENT Neural Interface System - Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Not applicableRecruitingJohns Hopkins University52027-01-012026-10-09
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
Q-Cells - Amyotrophic Lateral Sclerosis
Phase 1 / Phase 2Not yet recruitingQ Therapeutics, Inc.302026-12-012026-07-08
Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS
nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS)
Phase 1 / Phase 2Enrolling by invitationn-Lorem Foundation12026-12-012026-07-14
Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
β-hydroxy-β-methylbutyrate (HMB) - Amyotrophic Lateral Sclerosis ALS
Phase 1Not yet recruitingDuke University1002026-12-012026-11-04
Brain-Computer Interface Communication Device for People With ALS
Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device - Amyotrophic Lateral Sclerosis
Not applicableRecruitingCognixion302026-11-152026-10-16
Endovascular Brain-Computer Interface for Upper-Limb Paralysis
Endovascular Venous BCI Type-A Sensor, BCI-Triggered Functional Electrical Stimulation, BCI-Controlled Bionic Robotic Arm - Stroke, Hemiplegia
Not applicableNot yet recruitingWei Wu22026-11-022026-11-13
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
Sulforaphane and Bacillus coagulans GBI-30, 6086 - Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
Not applicableNot yet recruitingLiu Qing152026-11-012026-11-06
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
Orelabrutinib - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingLiu Qing182026-11-012026-11-06
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
IBM, Inclusion Body Myositis
RecruitingJohns Hopkins University302026-11-012026-10-28
REstoration of Communication and LAnguage With Intracortical Microelectrodes
RECLAIM System - Amyotrophic Lateral Sclerosis (ALS), locked-in Syndrome
Not applicableNot yet recruitingThe University of Texas Health Science Center, Houston42026-11-012026-11-12
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
LY3873862, CYP450 Drug Cocktail, Placebo - Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Phase 1Not yet recruitingEli Lilly and Company322026-11-012026-11-13
An Early Feasibility Study of a Robotically Implanted Brain-Computer Interface for Neural Control of External Devices in Spinal Cord Injury, Amyotrophic Lateral Sclerosis, and Chronic Ischemic Stroke
N1 Implant, R1 Robot - Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Not applicableRecruitingNeuralink Corp102026-11-012026-11-12
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Chronic speech BCI - Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Not applicableNot yet recruitingUniversity Hospital, Grenoble32026-10-102026-07-13
A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)
BIIB147, Placebo - Amyotrophic Lateral Sclerosis
Phase 1 / Phase 2RecruitingBiogen692026-10-072026-11-12
iBCI Optimization for Veterans With Paralysis
Mobile neural decoding platform (mobile iBCI) - Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development22026-10-022026-07-27
Development in Home Mechanical Ventilation for Patient With Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis, Home Mechanical Ventilation
Not yet recruitingCopenhagen University Hospital, Rigshospitalet4002026-10-012026-09-15

Showing 20 of 978. Sign in to see all of them.

Narrower conditions

Motor Neuron Disease (146)  ·  Parkinson Disease (49)  ·  Neurodegenerative Diseases (48)  ·  Neuromuscular Diseases (40)  ·  Spinal Cord Injuries (39)  ·  Alzheimer Disease (34)  ·  Frontotemporal Dementia (30)  ·  Multiple Sclerosis (30)  ·  Muscular Atrophy, Spinal (30)  ·  Nervous System Diseases (27)  ·  Stroke (26)  ·  Quadriplegia (22)  ·  Muscular Dystrophies (19)  ·  Movement Disorders (16)

Broader conditions

Metabolic Diseases (977)  ·  Nutritional and Metabolic Diseases (977)  ·  Proteostasis Deficiencies (977)  ·  Spinal Cord Diseases (973)  ·  TDP-43 Proteinopathies (972)  ·  Central Nervous System Diseases (969)  ·  Nervous System Diseases (951)  ·  Neuromuscular Diseases (938)  ·  Neurodegenerative Diseases (930)  ·  Motor Neuron Disease (832)  ·  Pathological Conditions, Signs and Symptoms (149)  ·  Brain Diseases (109)  ·  Signs and Symptoms (103)  ·  Neurologic Manifestations (84)  ·  Pathologic Processes (74)

Interventions

Riluzole (24)  ·  Blood Specimen Collection (13)  ·  Spinal Puncture (9)  ·  Dexpramipexole (8)  ·  Edaravone (8)  ·  sodium phenylbutyrate and taurursodiol (7)  ·  CK-2017357 (6)  ·  Noninvasive Ventilation (6)  ·  Sodium Chloride (6)  ·  Transcranial Magnetic Stimulation (6)  ·  Creatine (5)  ·  Memantine (5)  ·  arimoclomol (5)  ·  Brain-Computer Interfaces (4)  ·  Copper (4)

Sponsors

Peking University Third Hospital (21)  ·  Assistance Publique - Hôpitaux de Paris (20)  ·  Massachusetts General Hospital (20)  ·  Johns Hopkins University (12)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (11)  ·  University of Michigan (11)  ·  Drexel University College of Medicine (10)  ·  Mayo Clinic (10)  ·  Biogen (9)  ·  Cytokinetics (9)  ·  Knopp Biosciences (9)  ·  Merit E. Cudkowicz, MD (9)  ·  Amylyx Pharmaceuticals Inc. (8)  ·  Duke University (8)  ·  University Hospital, Tours (8)

Countries

United States (439)  ·  France (130)  ·  Italy (88)  ·  Canada (81)  ·  Germany (75)  ·  United Kingdom (68)  ·  Netherlands (65)  ·  Belgium (57)  ·  China (55)  ·  Spain (55)  ·  Australia (43)  ·  Sweden (33)  ·  Ireland (32)  ·  Poland (28)  ·  Japan (20)

Top investigators

Merit Cudkowicz, MD (10)  ·  Jeremy Shefner, MD, PhD (8)  ·  Bjorn Oskarsson, MD (6)  ·  Dominic Rowe, MD (5)  ·  Dongsheng Fan (5)  ·  Merit Cudkowicz, MD, MSc (5)  ·  Terry Heiman-Patterson, MD (5)  ·  Benjamin R Brooks, MD (4)  ·  Hamid Gourabi, PhD (4)  ·  Jakub M Antczak, MD (4)  ·  Jane Huggins, PhD (4)

Results publications

PMID 36008843, PMID 16434671, PMID 17980667, PMID 19251627, PMID 22415951, PMID 22529995, PMID 23300829, PMID 23463272, PMID 23952636, PMID 24067398, PMID 25982504, PMID 26751635, PMID 29287521, PMID 30124008, PMID 30814647, PMID 32896088, PMID 34433481, PMID 34536404, PMID 35532908, PMID 35577511, PMID 35790423, PMID 37254449, PMID 37396808, PMID 38010108, PMID 39457678, PMID 40067754, PMID 40067755, PMID 40067821, PMID 41224659, PMID 41366786, PMID 10540002, PMID 11015796, PMID 11050032, PMID 11586297, PMID 11750036, PMID 14718694, PMID 15084121, PMID 15505150, PMID 15657798, PMID 15790844, PMID 15823706, PMID 15831718, PMID 16267188, PMID 16636275, PMID 16741123, PMID 16822964, PMID 16849828, PMID 16894118, PMID 16900450, PMID 17018025

NIH funding

2023 (10), 2017 (6), 2025 (5), 2019 (3), U54NS092091 (3), 1OT2NS136938 (2), 1OT2NS136939 (2), 2014 (2), 2015 (2), P01AG066597 (2), P01NS084974 (2), R01DC021714 (2), U01NS049640 (2), 1DP2DC021055 (1), 2016 (1)